Not So Fast, Schering ... er, Merck ... er, Whoever You Are

Merck (NYSE: MRK  ) might have thought it would be able to get away with it, but Johnson & Johnson (NYSE: JNJ  ) isn't putting up with Merck's games.

Merck got cute with its acquisition of Schering-Plough (NYSE: SGP  ) by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move has a purpose: Schering-Plough's overseas marketing deal for Johnson & Johnson's anti-inflammatory Remicade and its follow-on Simponi has a provision that allows Johnson & Johnson to terminate the partnership if a company takes control of Schering-Plough.

In Securities and Exchange Commission documents, Schering-Plough said that earlier this month Johnson & Johnson told Schering-Plough that it plans to seek arbitration over whether Johnson & Johnson can terminate the contract given the circumstances of the reverse merger.

Partnerships and acquisitions hardly ever meld well together. Earlier this month, Japanese drugmaker Eisai said that it plans to end its partnership with Pfizer (NYSE: PFE  ) to market its Alzheimer's drug, Aricept, after Pfizer buys Wyeth (NYSE: WYE  ) , because Wyeth has a phase 3 Alzheimer's drug in development with Elan (NYSE: ELN  ) .

The stakes of the arbitration are huge for Merck. The $2.1 billion worth of Remicade sales last year were about 10% of Schering-Plough's adjusted sales, which include sales from its cholesterol drugs partnership with Merck. And Simponi is a potential blockbuster in its own right.

Whether the feud will go that far remains to be seen. I'm not sure either company thinks it's on firm enough legal ground to roll the dice and let an arbitrator decide the fate of Remicade and Simponi. Instead it seems likely that the companies will negotiate and work out a compromise. That'll likely mean that Merck ends up getting less than the full value of what Schering-Plough is worth, but won't lose the two drugs all together.

While not ideal, it's likely what investors in Merck and Schering-Plough will have to settle for.

This Foolishness still has full value:

Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Elan is a Rule Breakers selection. Pfizer is a recommendation of the Inside Value newsletter. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 904796, ~/Articles/ArticleHandler.aspx, 10/21/2014 10:09:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement